Author:
Bonnet Emmanuel,Daures Jean-Pierre,Landais Paul
Abstract
AbstractIn France, more than 10 million women at ”average” risk of breast cancer (BC), are included in the organized BC screening. Existing predictive models of BC risk are not adapted to the French population. Thus, we set up a new score in the French Hérault region and looked for subgroups at a graded level of risk in women at ”average” risk. We recruited a retrospective cohort of women, aged 50 to 60, who underwent the organized BC screening, and included 2241 non-cancer women and 527 who developed a BC during a 12-year follow-up period (2006-2018). The risk factors identified were high breast density (ACR BI-RADS grading)(B vs A: HR = 1.41, 95%CI [1.05; 1.9], p = 0.023; C vs A: HR = 1.65 [1.2; 2.27], p = 0.02 ; D vs A: HR = 2.11 [1.25;3.58], p = 0.006), a history of maternal breast cancer (HR = 1.61 [1.24; 2.09], p < 0.001), and socioeconomic difficulties (HR 1.23 [1.09; 1.55], p = 0.003). While early menopause (HR = 0.36 [0.13; 0.99], p = 0.003) and an age at menarche after 12 years (HR = 0.77 [0.63; 0.95], p = 0.047) were protective factors. We identified 3 groups at risk: lower, average, and higher, respectively. A low threshold was characterized at 1.9% of 12-year risk and a high threshold at 4.5% 12-year risk. Mean 12-year risks in the 3 groups of risk were 1.37%, 2.68%, and 5.84%, respectively. Thus, 12% of women presented a level of risk different from the average risk group, corresponding to 600,000 women involved in the French organized BC screening, enabling to propose a new strategy to personalize the national BC screening. On one hand, for women at lower risk, we proposed to reduce the frequency of mammograms and on the other hand, for women at higher risk, we suggested intensifying surveillance.
Funder
Nîmes University Hospital
Université de Montpellier
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Santé publique france. Sante publique france - Cancers. Tech. Rep. https://www.santepubliquefrance.fr/maladies-et-traumatismes/cancers. (2021).
2. Lefeuvre, D., Catajar, N., Le, C., Benjamin, B. & Bousquet, P. J. Dépistage du cancer du sein : impact sur les trajectoires de soins. Tech. Rep., Institut national du cancer (2018). https://www.e-cancer.fr/content/download/238001/3268333/file/Depistage_du_cancer_du_sein_impact_sur_les_trajctoires_de_soins_mel_20180608.pdf.
3. Jay, N., Nuemi, G., Gadreau, M. & Quantin, C. A data mining approach for grouping and analyzing trajectories of care using claim data: The example of breast cancer. BMC Med. Informatics Decis. Mak.https://doi.org/10.1186/1472-6947-13-130 (2013).
4. Haute Autorité de Santé. Dépistage du cancer du sein en France : identification des femmes à haut risque et modalités de dépistage. Tech. Rep., HAS (2014). www.has-sante.fr.
5. Santé publique France. Taux de participation au programme de dépistage organisé du cancer du sein 2018-2019 et évolution depuis 2005. Tech. Rep., Santé publique France (2020). https://www.santepubliquefrance.fr/maladies-et-traumatismes/cancers/cancer-du-sein/articles/taux-de-participation-au-programme-de-depistage-organise-du-cancer-du-sein-2018-2019-et-evolution-depuis-2005.